Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies

NCT02120157 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Myeloablative Conditioning
HLA-mismatched Bone Marrow Transplantation
Graft Survival
Transplantation, Bone Marrow

Interventions

DRUG: Cyclophosphamide
RADIATION: TBI
DRUG: Busulfan
OTHER: Unmanipulated Bone Marrow
DRUG: Tacrolimus
DRUG: Mycophenolate mofetil

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins